Centivax has commenced participant dosing in its Phase Ia clinical trial, assessing Centi-Flu 01, a pan-influenza universal ...

Moderna’s mRNA influenza vaccine faces US regulatory delays after a refusal-to-file letter from top FDA official Dr Vinay Prasad.

By Siddhi Mahatole and Gnaneshwar Rajan Feb 11 (Reuters) - The United States will take part in a World Health Organization meeting at the end of the month to determine the composition of upcoming ...

Refusal to review the submission is inconsistent with feedback at pre-Phase 3 and pre-submission consultations; Moderna ...

Centivax, Inc., a clinical-stage biotechnology company engineering vaccines and therapies for durable, universal protection against highly diverse targets, today announced that the first participants ...

Moderna claimed that the decision, issued by top vaccine regulator Vinay Prasad, was “inconsistent” with prior FDA ...

Flu vaccination rates among adults show early signs of stabilizing after several years of decline, though pediatric rates remain historically low, preliminary CDC data shows. The CDC’s Weekly ...

The U.S. will participate in the World Health Organization’s (WHO) upcoming meeting on the composition of the influenza ...

The FDA declined to review Moderna's mRNA influenza vaccine due to inadequate clinical trial comparators for older adults.

This week, vaccine manufacturer Moderna revealed that Vinaya Prasad, the top vaccine regulator at the Food and Drug Administration (FDA)—which is a part of HHS— declined to even consider the safety ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. While the media's attention has focused on unproven links between ...

By Sneha S K Feb 10 (Reuters) - The U.S. Food and Drug Administration will not review Moderna's approval application for its ...